Key result
Preoperative dipyridamole-thallium testing did not significantly predict adverse cardiac events after vascular surgery (7.9% vs 3.4%, p=NS), whereas having ≥1 Eagle criteria increased risk.
Why the study?
Does preoperative dipyridamole-thallium imaging predict adverse cardiac events in patients undergoing vascular surgery?
Population
211 vascular procedures in patients undergoing vascular surgery at a Veteran Affairs hospital
Comparison
Preoperative dipyridamole-thallium imaging vs No preoperative PTHAL imaging (n=148)
Design
Cohort
Authors
Loading...
May not warrant dipyridamole-thallium testing before vascular surgery; leaves open incremental value of imaging over Eagle criteria.
Observational (n=211)
No
Does preoperative dipyridamole-thallium imaging predict adverse cardiac events in patients undergoing vascular surgery?
Absolute Event Rate: 7.9% vs 3.4%
p-value: p=NS
Preoperative dipyridamole-thallium imaging does not predict postoperative cardiac events in vascular surgery patients, whereas clinical evaluation using Eagle criteria is predictive.
Virgilio et al. (1998) conducted an observational in Vascular surgery (n=211). Preoperative dipyridamole-thallium (PTHAL) testing vs. No preoperative PTHAL testing was evaluated on Adverse cardiac events (p=NS). Preoperative dipyridamole-thallium testing did not significantly predict adverse cardiac events after vascular surgery (7.9% vs 3.4%, p=NS), whereas having ≥1 Eagle criteria increased risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: